Pharming Group (PHAR)
(Delayed Data from NSDQ)
$8.00 USD
+0.58 (7.82%)
Updated Aug 14, 2024 02:22 PM ET
4-Sell of 5 4
C Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Pharming Group NV Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 213 | 208 | 192 | 192 | 74 |
Receivables | 46 | 28 | 30 | 33 | 29 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 57 | 42 | 27 | 20 | 16 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 316 | 278 | 249 | 245 | 119 |
Net Property & Equipment | 10 | 10 | 13 | 11 | 10 |
Investments & Advances | 10 | 10 | 9 | 7 | 6 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 30 | 23 | 21 | 30 | 32 |
Intangibles | 71 | 75 | 84 | 88 | 79 |
Deposits & Other Assets | 2 | 1 | 1 | 0 | 3 |
Total Assets | 463 | 426 | 397 | 389 | 256 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 73 | 54 | 42 | 44 | 41 |
Current Portion Long-Term Debt | 2 | 2 | 2 | 2 | 51 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 23 | 20 |
Total Current Liabilities | 78 | 60 | 47 | 71 | 114 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 137 | 132 | 139 | 139 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 19 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 244 | 221 | 204 | 219 | 138 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 8 | 8 | 7 | 7 | 7 |
Capital Surplus | 478 | 462 | 455 | 453 | 439 |
Retained Earnings | -265 | -256 | -273 | -295 | -333 |
Other Equity | -2 | -9 | 3 | 5 | 4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 219 | 205 | 193 | 171 | 117 |
Total Liabilities & Shareholder's Equity | 463 | 426 | 397 | 389 | 256 |
Total Common Equity | 219 | 205 | 193 | 171 | 117 |
Shares Outstanding | 67.10 | 65.60 | 64.80 | 63.80 | NA |
Book Value Per Share | 3.26 | 3.12 | 2.98 | 2.67 | 0.00 |
Fiscal Year End for Pharming Group NV Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 160 | 202 | 213 | 198 | -99,807 |
Receivables | 51 | 39 | 46 | 41 | 33 |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 59 | 56 | 57 | 53 | 53 |
Other Current Assets | 0 | 0 | 0 | 0 | NA |
Total Current Assets | 271 | 297 | 316 | 292 | 279 |
Net Property & Equipment | 9 | 9 | 10 | 10 | 10 |
Investments & Advances | 7 | 8 | 10 | 9 | 10 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 39 | 36 | 30 | 27 | 27 |
Intangibles | 67 | 68 | 71 | 70 | 73 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 416 | 442 | 463 | 436 | 430 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 73 | 69 | 73 | 63 | 59 |
Current Portion Long-Term Debt | 3 | 135 | 2 | 2 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 0 | 0 | 0 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 80 | 207 | 78 | 68 | 65 |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 87 | 0 | 137 | 130 | 134 |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | NA | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 195 | 236 | 244 | 227 | 229 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 8 | 8 | 8 | 8 | 8 |
Capital Surplus | 487 | 480 | 478 | 476 | 464 |
Retained Earnings | -280 | -277 | -265 | -263 | -265 |
Other Equity | 6 | -4 | -2 | -11 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 221 | 206 | 219 | 210 | 200 |
Total Liabilities & Shareholder's Equity | 416 | 442 | 463 | 436 | 430 |
Total Common Equity | 221 | 206 | 219 | 210 | 100,199 |
Shares Outstanding | 67.80 | 67.10 | 67.10 | 66.90 | 65.60 |
Book Value Per Share | 3.26 | 3.07 | 3.26 | 3.14 | 1,527.43 |